PK of Sugammadex in Renal Insufficiency

Phase 1, open-label trial of Sugammadex in neuromuscular blockade (NMB) (6 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Drug Concentration-time Curve From Time Zero to Infinity at Day 35, Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration at Day 35 and 4 more. Started Dec 2013; status: completed.